Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | DTYMK | P23919 | 4/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16203365 | 0.91 | POLB (0.64) | POLBENPP1P2RY1DTYMKSRC | |
| SCHEMBL19051966 | 0.90 | POLB (0.74) | POLBENPP1P2RY1DTYMKNT5E | |
| SCHEMBL16248673 | 0.90 | POLB (0.74) | POLBENPP1P2RY1DTYMKNT5E | |
| SCHEMBL19389400 | 0.90 | POLB (0.59) | POLBENPP1P2RY1HIF1ADTYMK | |
| SCHEMBL16846732 | 0.87 | POLB (0.56) | POLBENPP1P2RY1HIF1ADTYMK | |
| SCHEMBL24829433 | 0.85 | POLB (0.73) | POLBENPP1P2RY1DTYMKSRC | |
| SCHEMBL13983913 | 0.85 | POLB (0.73) | POLBENPP1P2RY1DTYMKSRC | |
| SCHEMBL19389393 | 0.85 | POLB (0.59) | POLBENPP1P2RY1HIF1ADTYMK | |
| SCHEMBL2048956 | 0.82 | HIF1A (0.75) | HIF1A | |
| SCHEMBL2408903 | 0.82 | HIF1A (0.75) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714421-B2 | Compositions and methods | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9382540-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | ISIS PHARMACEUTICALS, INC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160090595-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160017323-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9181550-B2 | Compositions and methods for modulating apolipoprotein (a) expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181549-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9163239-B2 | Compositions and methods for modulating apolipoprotein C-III expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126719-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126720-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |